James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Orexigen Therapeutics, Inc. (OREX), Gap Inc. (GPS) and Rackspace Hosting, Inc. (RAX) Are 3 of Today’s Worst Stocks

Orexigen Therapeutics (OREX), Gap (GPS) and Rackspace Hosting (RAX) couldn't win for losing on Tuesday.

CSCO Stock Earnings Preview: Cisco Going From Good to Great

Already riding high, CSCO could really begin to rally in the wake of Wednesday's earnings call.

Why Etsy Inc. (ETSY), Vertex Pharmaceuticals Incorporated (VRTX) and Noble Energy, Inc. (NBL) Are 3 of Today’s Worst Stocks

Etsy (ETSY), Vertex Pharmaceuticals (VRTX) and Noble Energy (NBL) got the new week started on the wrong foot.

Why MannKind (MNKD), Monster Beverage (MNST) and Cerner (CERN) Are 3 of Today’s Worst Stocks

MannKind Corporation (MNKD), Monster Beverage (MNST) and Cerner Corporation (CERN) would love to have a do-over of Friday's trading session.

10 Healthcare Stocks Taking Aim at Cancer

Amgen, Inc. (NASDAQ:AMGN), Celgene Corporation (NASDAQ:CELG), Inovio Pharmaceuticals Inc. (NASDAQ:INO) and several other healthcare stocks are cancer medicine plays worth a look.